Sonoma Biotherapeutics
John brings extensive experience in characterizing a diverse array of immune subsets associated with protection from disease while developing novel tools to support and ensure progress in programs throughout the drug development pipeline from early discovery to late-stage projects.
Prior to joining Sonoma, John developed subject matter expertise in end-to-end lab build-outs at several Seattle sites, including leading the execution of lab design, infrastructure, and implementation of operations processes to enable the immuno-oncology research program at Celgene Seattle.
John received his B.S. in Cell and Molecular Biology from the University of Washington. He has worked in immunology labs for 20 years in various focus areas including HIV, Inflammation, and Oncology in both academia and industry settings that include the HIV Vaccine Trials Network at the Fred Hutch, Benaroya Research Institute, Novo Nordisk, and Celgene.
John is a member of Sonoma’s Product Validation Group in Seattle, with responsibilities that include establishing cellular parameters for analytical development to support in-process analysis.
This person is not in the org chart
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.